<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Marinac CR</submitter><funding>SU2C</funding><funding>NCI NIH HHS</funding><funding>American Society of Hematology</funding><funding>NCI NIH NCI</funding><funding>NCI NIH</funding><pagination>479-485</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8825752</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(2)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Inflammation is important in multiple myeloma pathogenesis, and regular aspirin use has been shown to confer a reduced risk of multiple myeloma. The influence of aspirin on survival after multiple myeloma diagnosis is unknown.&lt;h4>Methods&lt;/h4>We identified 436 men and women diagnosed with multiple myeloma between 1980 and 2016 in the Health Professionals Follow-up Study and the Nurses' Health Study who reported aspirin intake biennially on follow-up questionnaires. Using multivariable Cox proportional hazards regression models, we estimated HRs and 95% confidence intervals (CI) associated with the effect of aspirin use on multiple myeloma-specific and overall mortality.&lt;h4>Results&lt;/h4>Compared with nonusers, participants who used aspirin after diagnosis had a multivariabl</pubmed_abstract><journal>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</journal><pubmed_title>Regular Aspirin Use and Mortality in Patients with Multiple Myeloma.</pubmed_title><pmcid>PMC8825752</pmcid><funding_grant_id>PF-17–231–01-CCE</funding_grant_id><funding_grant_id>K07 CA115687</funding_grant_id><funding_grant_id>F32 CA220859</funding_grant_id><funding_grant_id>R03 CA204825</funding_grant_id><funding_grant_id>U01 CA167552</funding_grant_id><funding_grant_id>P01 CA87969</funding_grant_id><funding_grant_id>P01 CA087969</funding_grant_id><funding_grant_id>AACR-DT-28-18</funding_grant_id><funding_grant_id>R21 CA198239</funding_grant_id><funding_grant_id>R01 CA127435</funding_grant_id><funding_grant_id>K22 CA251648</funding_grant_id><funding_grant_id>UM1 CA186107</funding_grant_id><pubmed_authors>Ghobrial IM</pubmed_authors><pubmed_authors>Lee DH</pubmed_authors><pubmed_authors>Colditz GA</pubmed_authors><pubmed_authors>Marinac CR</pubmed_authors><pubmed_authors>Rosner B</pubmed_authors><pubmed_authors>Birmann BM</pubmed_authors><pubmed_authors>Bustoros M</pubmed_authors><pubmed_authors>Rebbeck TR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Regular Aspirin Use and Mortality in Patients with Multiple Myeloma.</name><description>&lt;h4>Background&lt;/h4>Inflammation is important in multiple myeloma pathogenesis, and regular aspirin use has been shown to confer a reduced risk of multiple myeloma. The influence of aspirin on survival after multiple myeloma diagnosis is unknown.&lt;h4>Methods&lt;/h4>We identified 436 men and women diagnosed with multiple myeloma between 1980 and 2016 in the Health Professionals Follow-up Study and the Nurses' Health Study who reported aspirin intake biennially on follow-up questionnaires. Using multivariable Cox proportional hazards regression models, we estimated HRs and 95% confidence intervals (CI) associated with the effect of aspirin use on multiple myeloma-specific and overall mortality.&lt;h4>Results&lt;/h4>Compared with nonusers, participants who used aspirin after diagnosis had a multivariabl</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-04T19:40:34.867Z</modification><creation>2025-04-04T19:40:34.867Z</creation></dates><accession>S-EPMC8825752</accession><cross_references><pubmed>34862208</pubmed><doi>10.1158/1055-9965.epi-21-0946</doi><doi>10.1158/1055-9965.EPI-21-0946</doi></cross_references></HashMap>